Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCI-COG Pediatric MATCH: Tipifarnib in HRAS-Altered Tumors
NCT04284774Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tipifarnib in solid tumor, lymphoma, histiocytic disorder, sponsored by National Cancer Institute. Started Oct 2020; status: active, not recruiting.
02
Drugs
tipifarnib
03
Conditions
solid tumorlymphomahistiocytic disorder
Beyond the preview
Go deeper on NCT04284774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284774.